Fairview Capital Investment Management LLC grew its position in Becton Dickinson and Co (NYSE:BDX) by 29.3% during the 4th quarter, HoldingsChannel reports. The fund owned 11,460 shares of the medical instruments supplier’s stock after buying an additional 2,597 shares during the quarter. Fairview Capital Investment Management LLC’s holdings in Becton Dickinson and were worth $2,453,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Amalgamated Bank lifted its position in shares of Becton Dickinson and by 9.8% in the fourth quarter. Amalgamated Bank now owns 29,659 shares of the medical instruments supplier’s stock valued at $6,349,000 after acquiring an additional 2,637 shares in the last quarter. Calamos Wealth Management LLC purchased a new position in shares of Becton Dickinson and in the fourth quarter valued at approximately $221,000. Assetmark Inc. lifted its position in shares of Becton Dickinson and by 4,895.0% in the fourth quarter. Assetmark Inc. now owns 30,769 shares of the medical instruments supplier’s stock valued at $6,586,000 after acquiring an additional 30,153 shares in the last quarter. Mackenzie Financial Corp lifted its position in shares of Becton Dickinson and by 32.2% in the fourth quarter. Mackenzie Financial Corp now owns 960,926 shares of the medical instruments supplier’s stock valued at $205,696,000 after acquiring an additional 234,111 shares in the last quarter. Finally, Carnegie Capital Asset Management LLC purchased a new position in shares of Becton Dickinson and in the fourth quarter valued at approximately $449,000. Institutional investors and hedge funds own 77.50% of the company’s stock.
In other Becton Dickinson and news, EVP James W. Borzi sold 4,048 shares of Becton Dickinson and stock in a transaction on Monday, February 26th. The stock was sold at an average price of $224.98, for a total value of $910,719.04. Following the sale, the executive vice president now owns 5,334 shares in the company, valued at $1,200,043.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Timothy M. Ring sold 176 shares of Becton Dickinson and stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $218.27, for a total value of $38,415.52. Following the completion of the sale, the director now owns 170,688 shares in the company, valued at approximately $37,256,069.76. The disclosure for this sale can be found here. Insiders sold 273,885 shares of company stock worth $59,686,694 in the last 90 days. Company insiders own 1.00% of the company’s stock.
Becton Dickinson and (NYSE:BDX) last posted its earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 EPS for the quarter, beating the Zacks’ consensus estimate of $2.41 by $0.07. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. The company had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. During the same quarter in the previous year, the business earned $2.33 earnings per share. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. analysts forecast that Becton Dickinson and Co will post 10.94 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Friday, March 9th will be given a $0.75 dividend. The ex-dividend date of this dividend is Thursday, March 8th. This represents a $3.00 dividend on an annualized basis and a yield of 1.33%. Becton Dickinson and’s dividend payout ratio is currently 229.01%.
Several equities analysts have recently weighed in on BDX shares. Zacks Investment Research upgraded Becton Dickinson and from a “hold” rating to a “buy” rating and set a $240.00 target price on the stock in a research report on Wednesday, January 3rd. Deutsche Bank set a $260.00 price objective on Becton Dickinson and and gave the stock a “buy” rating in a research report on Friday, December 29th. Argus lifted their price objective on Becton Dickinson and to $235.00 and gave the stock a “buy” rating in a research report on Thursday, December 14th. They noted that the move was a valuation call. Stifel Nicolaus reiterated a “buy” rating and set a $245.00 price objective on shares of Becton Dickinson and in a research report on Friday, November 3rd. Finally, Bank of America reiterated a “buy” rating and set a $260.00 price objective on shares of Becton Dickinson and in a research report on Friday, January 19th. Four investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. Becton Dickinson and has a consensus rating of “Buy” and a consensus price target of $237.27.
Becton Dickinson and Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.